Litcius/Paper detail

Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study

Kaitlin R McCarter, Taylor Wolfgang, Senada Arabelovic, Xiaosong Wang, Kazuki Yoshida, Emily Banasiak, Grace Qian, Emily Kowalski, Kathleen M.M. Vanni, Nicole R. LeBoeuf, Elizabeth I. Buchbinder, Lydia Gedmintas, Lindsey A. MacFarlane, Deepak A. Rao, Nancy A. Shadick, Ellen M. Gravallese, Jeffrey A. Sparks

2023The Lancet Rheumatology39 citationsDOIOpen Access PDF

Topics & Concepts

MedicineRheumatoid arthritisInternal medicineAdverse effectCancerRheumatologyImmune checkpointOncologyImmune systemIpilimumabArthritisImmunologyCohortRetrospective cohort studyImmunotherapyCancer Immunotherapy and BiomarkersInflammatory Biomarkers in Disease PrognosisEconomic and Financial Impacts of Cancer
Mortality and immune-related adverse events after immune checkpoint inhibitor initiation for cancer among patients with pre-existing rheumatoid arthritis: a retrospective, comparative, cohort study | Litcius